Search research articles
Contact Us
Filters
Showing results (121-130 of 176) with videos related to
Page
of 18
Sort By:
Medicina Intensiva
|
March 24, 2015
Optimization of pre-emptive isolations in a polyvalent ICU through implementation of an intervention strategy
F Álvarez Lerma, J Granado Solano, A García Sanz, et al.
Antibiotics (Basel, Switzerland)
|
November 11, 2022
Suboptimal Concentrations of Ceftazidime/Avibactam (CAZ-AVI) May Select for CAZ-AVI Resistance in Extensively Drug-Resistant <i>Pseudomonas aeruginosa</i>: In Vivo and In Vitro Evidence
Inmaculada Lopez-Montesinos, María Milagro Montero, Sandra Domene-Ochoa, et al.
Open Forum Infectious Diseases
|
February 2, 2022
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of the Monoclonal Antibody MHAA4549A in Patients With Acute Uncomplicated Influenza A Infection
Jeremy J Lim, Sadia Dar, Dirk Venter, et al.
Scientific Reports
|
March 4, 2017
Chitosan-coated mesoporous MIL-100(Fe) nanoparticles as improved bio-compatible oral nanocarriers
T Hidalgo, M Giménez-Marqués, E Bellido, et al.
Scientific Reports
|
November 13, 2021
Impact of ceftolozane/tazobactam concentrations in continuous infusion against extensively drug-resistant Pseudomonas aeruginosa isolates in a hollow-fiber infection model
María M Montero, Sandra Domene-Ochoa, Carla López-Causapé, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases
|
April 18, 2015
Clinical features and outcomes of tuberculosis in transplant recipients as compared with the general population: a retrospective matched cohort study
N Benito, E García-Vázquez, J P Horcajada, et al.
Microbiology Spectrum
|
June 13, 2022
Comparison of Ceftolozane/Tazobactam Infusion Regimens in a Hollow-Fiber Infection Model against Extensively Drug-Resistant Pseudomonas aeruginosa Isolates
María Milagro Montero, Sandra Domene-Ochoa, Carla López-Causapé, et al.
Microbiology Spectrum
|
July 28, 2021
Time-Kill Evaluation of Antibiotic Combinations Containing Ceftazidime-Avibactam against Extensively Drug-Resistant Pseudomonas aeruginosa and Their Potential Role against Ceftazidime-Avibactam-Resistant Isolates
María M Montero, Sandra Domene Ochoa, Carla López-Causapé, et al.
Pneumonia (Nathan Qld.)
|
February 24, 2024
Safety and efficacy of favipiravir in COVID-19 patients with pneumonia. A randomized, double-blind, placebo-controlled study (FAVID)
Juan P Horcajada, Rebeca Aldonza, Mónica Real, et al.
Critical Care (London, England)
|
February 19, 2020
Intrapulmonary concentrations of meropenem administered by continuous infusion in critically ill patients with nosocomial pneumonia: a randomized pharmacokinetic trial
Adela Benítez-Cano, Sonia Luque, Luisa Sorlí, et al.
Page
of 18
Search research articles
Search
Showing results (121-130 of 176) with videos related to
Sort By:
Page
of 18
Medicina Intensiva
|
March 24, 2015
Optimization of pre-emptive isolations in a polyvalent ICU through implementation of an intervention strategy
F Álvarez Lerma, J Granado Solano, A García Sanz, et al.
Antibiotics (Basel, Switzerland)
|
November 11, 2022
Suboptimal Concentrations of Ceftazidime/Avibactam (CAZ-AVI) May Select for CAZ-AVI Resistance in Extensively Drug-Resistant <i>Pseudomonas aeruginosa</i>: In Vivo and In Vitro Evidence
Inmaculada Lopez-Montesinos, María Milagro Montero, Sandra Domene-Ochoa, et al.
Open Forum Infectious Diseases
|
February 2, 2022
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of the Monoclonal Antibody MHAA4549A in Patients With Acute Uncomplicated Influenza A Infection
Jeremy J Lim, Sadia Dar, Dirk Venter, et al.
Scientific Reports
|
March 4, 2017
Chitosan-coated mesoporous MIL-100(Fe) nanoparticles as improved bio-compatible oral nanocarriers
T Hidalgo, M Giménez-Marqués, E Bellido, et al.
Scientific Reports
|
November 13, 2021
Impact of ceftolozane/tazobactam concentrations in continuous infusion against extensively drug-resistant Pseudomonas aeruginosa isolates in a hollow-fiber infection model
María M Montero, Sandra Domene-Ochoa, Carla López-Causapé, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases
|
April 18, 2015
Clinical features and outcomes of tuberculosis in transplant recipients as compared with the general population: a retrospective matched cohort study
N Benito, E García-Vázquez, J P Horcajada, et al.
Microbiology Spectrum
|
June 13, 2022
Comparison of Ceftolozane/Tazobactam Infusion Regimens in a Hollow-Fiber Infection Model against Extensively Drug-Resistant Pseudomonas aeruginosa Isolates
María Milagro Montero, Sandra Domene-Ochoa, Carla López-Causapé, et al.
Microbiology Spectrum
|
July 28, 2021
Time-Kill Evaluation of Antibiotic Combinations Containing Ceftazidime-Avibactam against Extensively Drug-Resistant Pseudomonas aeruginosa and Their Potential Role against Ceftazidime-Avibactam-Resistant Isolates
María M Montero, Sandra Domene Ochoa, Carla López-Causapé, et al.
Pneumonia (Nathan Qld.)
|
February 24, 2024
Safety and efficacy of favipiravir in COVID-19 patients with pneumonia. A randomized, double-blind, placebo-controlled study (FAVID)
Juan P Horcajada, Rebeca Aldonza, Mónica Real, et al.
Critical Care (London, England)
|
February 19, 2020
Intrapulmonary concentrations of meropenem administered by continuous infusion in critically ill patients with nosocomial pneumonia: a randomized pharmacokinetic trial
Adela Benítez-Cano, Sonia Luque, Luisa Sorlí, et al.
Page
of 18